Status:
WITHDRAWN
Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
Lead Sponsor:
Université de Sherbrooke
Collaborating Sponsors:
Janssen Inc.
Conditions:
Type2 Diabetes
Heart Failure
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors (Canagliflozin) may have a beneficial role on cardiac energetic efficiency. Patients with type 2 diabetes and with HF d...
Detailed Description
Non-invasive Positron Emission Tomography (PET) imaging method allows to measure myocardial uptake and organ-specific partitioning of dietary fatty acids (DFA). It allows to study kidney, liver, skele...
Eligibility Criteria
Inclusion
- HbA1c 7.5 -10.5%;
- LVEF \< 40%;
- NYHA class 2 or 3;
- NT pro-BNP level \> 600 pg/mL;
- Being on a stable-dose metformin therapy max 2500 mg/day or other hypoglycemic therapy and RAAS-blocking agents for at least 8 weeks;
- Being on optimal and stable-doses of heart failure medication including diuretics for at least 4 weeks;
Exclusion
- age \<18 yo;
- NYHA class 4;
- Treatment with a fibrate or thiazolidinedione;
- Unstable or advanced renal failure;
- Unstable or new medical or surgical condition within the past 3 months;
- Heart failure caused by active inflammatory condition such as sarcoidosis or any form of myocarditis;
- History of diabetic ketoacidosis;
- Not on a stable regimen for at least 8 weeks before the screening visit;
- Female of child-bearing potential who is pregnant, breast feeding or intends to become pregnant or pre-menopausal female with a positive serum pregnancy test at the time of enrollment;
- Patients post bariatric surgery, or on weight loss medication;
- Contraindications to metformin, including allergy or intolerance;
- Hospitalization for heart failure within the 60 days prior to enrollment;
- Admission for an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within the 60 days prior to enrollment;
- Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment;
- Patients who are volume depleted based upon physical examination at the time of enrollment;
- Chronic disabling illness;
- History of substance abuse.
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03298009
Start Date
May 1 2018
End Date
June 30 2018
Last Update
December 13 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.